These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1290 related articles for article (PubMed ID: 31266892)
1. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892 [TBL] [Abstract][Full Text] [Related]
2. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297 [TBL] [Abstract][Full Text] [Related]
3. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116 [TBL] [Abstract][Full Text] [Related]
4. Dual roles of PARP-1 promote cancer growth and progression. Schiewer MJ; Goodwin JF; Han S; Brenner JC; Augello MA; Dean JL; Liu F; Planck JL; Ravindranathan P; Chinnaiyan AM; McCue P; Gomella LG; Raj GV; Dicker AP; Brody JR; Pascal JM; Centenera MM; Butler LM; Tilley WD; Feng FY; Knudsen KE Cancer Discov; 2012 Dec; 2(12):1134-49. PubMed ID: 22993403 [TBL] [Abstract][Full Text] [Related]
5. Olaparib for the treatment of metastatic prostate cancer. Dror CM; Wyatt AW; Chi KN Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071 [TBL] [Abstract][Full Text] [Related]
6. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819 [TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors in castration-resistant prostate cancer. Tripathi A; Balakrishna P; Agarwal N Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972 [TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
10. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors. Hankey W; Chen Z; Wang Q Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298 [TBL] [Abstract][Full Text] [Related]
11. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211 [TBL] [Abstract][Full Text] [Related]
12. Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly. Yang CS; Jividen K; Kamata T; Dworak N; Oostdyk L; Remlein B; Pourfarjam Y; Kim IK; Du KP; Abbas T; Sherman NE; Wotton D; Paschal BM Nat Commun; 2021 May; 12(1):2705. PubMed ID: 33976187 [TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development. Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527 [TBL] [Abstract][Full Text] [Related]
15. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942 [TBL] [Abstract][Full Text] [Related]
16. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812 [TBL] [Abstract][Full Text] [Related]
17. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer. Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587 [TBL] [Abstract][Full Text] [Related]
19. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]